DK3419979T3 - 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser - Google Patents
6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser Download PDFInfo
- Publication number
- DK3419979T3 DK3419979T3 DK17711330.5T DK17711330T DK3419979T3 DK 3419979 T3 DK3419979 T3 DK 3419979T3 DK 17711330 T DK17711330 T DK 17711330T DK 3419979 T3 DK3419979 T3 DK 3419979T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxazine
- pyrazolo
- dihydro
- carboxamide compounds
- carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298657P | 2016-02-23 | 2016-02-23 | |
| PCT/IB2017/050844 WO2017145013A1 (en) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3419979T3 true DK3419979T3 (da) | 2020-03-23 |
Family
ID=58347718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17711330.5T DK3419979T3 (da) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10323042B2 (da) |
| EP (1) | EP3419979B1 (da) |
| JP (1) | JP6837072B2 (da) |
| KR (1) | KR102148587B1 (da) |
| CN (2) | CN113332292A (da) |
| AU (1) | AU2017223132B2 (da) |
| BR (1) | BR112018015191B1 (da) |
| CA (1) | CA3015166C (da) |
| DK (1) | DK3419979T3 (da) |
| ES (1) | ES2775674T3 (da) |
| HU (1) | HUE048658T2 (da) |
| IL (1) | IL260536B (da) |
| MX (1) | MX2018010177A (da) |
| PL (1) | PL3419979T3 (da) |
| PT (1) | PT3419979T (da) |
| RU (1) | RU2719599C2 (da) |
| SG (1) | SG11201806383TA (da) |
| WO (1) | WO2017145013A1 (da) |
| ZA (1) | ZA201804619B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2989456C (en) * | 2015-06-17 | 2022-01-04 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| AU2019226585A1 (en) * | 2018-03-01 | 2020-10-08 | Board Of Regents, The University Of Texas System | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
| CA3108792A1 (en) * | 2018-09-10 | 2020-03-19 | Kaken Pharmaceutical Co., Ltd. | Novel heteroaromatic amide derivative and medicament containing the same |
| EP3914701A4 (en) * | 2019-01-23 | 2022-10-19 | Path Therapeutics Inc. | METHODS OF TREATMENT OF EPILEPSY VIA PHOSPHODIESTERASE 4-(PDE4) INHIBITION |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1308461A3 (en) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| AU743827B2 (en) | 1997-04-09 | 2002-02-07 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| AU4178601A (en) | 2000-02-24 | 2001-09-03 | Univ Washington | Humanized antibodies that sequester abeta peptide |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| AR039774A1 (es) | 2002-05-01 | 2005-03-02 | Wyeth Corp | 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas |
| US20040132708A1 (en) | 2002-05-01 | 2004-07-08 | Wyeth | Process for preparing 6-alkylidene penem derivatives |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| PL377769A1 (pl) | 2002-10-09 | 2006-02-20 | Rinat Neuroscience Corp. | Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MXPA06015275A (es) * | 2004-07-01 | 2007-03-15 | Merck & Co Inc | Inhibidores de quinasa mitotica. |
| SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY |
| MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| CA2608018C (en) | 2005-05-12 | 2010-07-13 | Pfizer Inc. | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| AP2408A (en) | 2006-04-21 | 2012-05-30 | Pfizer Prod Inc | Pyridine[3,4-B]pyrazinones. |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| MX2009007782A (es) | 2007-01-22 | 2009-07-31 | Pfizer Prod Inc | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. |
| DK2297106T3 (da) * | 2008-05-27 | 2014-10-06 | Astrazeneca Ab | Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| AR079967A1 (es) | 2010-01-26 | 2012-02-29 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos |
| WO2014128585A1 (en) | 2013-02-19 | 2014-08-28 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
| EP3177624B1 (en) * | 2014-08-06 | 2019-05-01 | Pfizer Inc | Imidazopyridazine compounds |
-
2017
- 2017-02-15 CN CN202110445183.8A patent/CN113332292A/zh active Pending
- 2017-02-15 RU RU2018128781A patent/RU2719599C2/ru active
- 2017-02-15 DK DK17711330.5T patent/DK3419979T3/da active
- 2017-02-15 EP EP17711330.5A patent/EP3419979B1/en active Active
- 2017-02-15 KR KR1020187023853A patent/KR102148587B1/ko active IP Right Grant
- 2017-02-15 PL PL17711330T patent/PL3419979T3/pl unknown
- 2017-02-15 SG SG11201806383TA patent/SG11201806383TA/en unknown
- 2017-02-15 HU HUE17711330A patent/HUE048658T2/hu unknown
- 2017-02-15 BR BR112018015191-2A patent/BR112018015191B1/pt active IP Right Grant
- 2017-02-15 JP JP2018544154A patent/JP6837072B2/ja active Active
- 2017-02-15 WO PCT/IB2017/050844 patent/WO2017145013A1/en active Application Filing
- 2017-02-15 US US16/074,290 patent/US10323042B2/en active Active
- 2017-02-15 CA CA3015166A patent/CA3015166C/en active Active
- 2017-02-15 PT PT177113305T patent/PT3419979T/pt unknown
- 2017-02-15 AU AU2017223132A patent/AU2017223132B2/en active Active
- 2017-02-15 ES ES17711330T patent/ES2775674T3/es active Active
- 2017-02-15 CN CN201780013020.4A patent/CN108699080B/zh active Active
- 2017-02-15 MX MX2018010177A patent/MX2018010177A/es unknown
-
2018
- 2018-07-11 IL IL260536A patent/IL260536B/en active IP Right Grant
- 2018-07-11 ZA ZA2018/04619A patent/ZA201804619B/en unknown
-
2019
- 2019-05-31 US US16/427,627 patent/US10738063B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180101568A (ko) | 2018-09-12 |
| CA3015166C (en) | 2021-08-03 |
| BR112018015191A2 (pt) | 2018-12-18 |
| JP2019505558A (ja) | 2019-02-28 |
| PL3419979T3 (pl) | 2020-06-29 |
| BR112018015191B1 (pt) | 2023-10-17 |
| RU2018128781A3 (da) | 2020-03-24 |
| AU2017223132B2 (en) | 2019-12-05 |
| MX2018010177A (es) | 2019-01-21 |
| AU2017223132A1 (en) | 2018-07-26 |
| CN108699080A (zh) | 2018-10-23 |
| US20190055262A1 (en) | 2019-02-21 |
| CN113332292A (zh) | 2021-09-03 |
| US10738063B2 (en) | 2020-08-11 |
| IL260536B (en) | 2020-10-29 |
| RU2719599C2 (ru) | 2020-04-21 |
| PT3419979T (pt) | 2020-03-26 |
| US20190300546A1 (en) | 2019-10-03 |
| EP3419979A1 (en) | 2019-01-02 |
| HUE048658T2 (hu) | 2020-07-28 |
| ZA201804619B (en) | 2020-12-23 |
| WO2017145013A1 (en) | 2017-08-31 |
| JP6837072B2 (ja) | 2021-03-03 |
| CN108699080B (zh) | 2021-05-14 |
| CA3015166A1 (en) | 2018-08-31 |
| RU2018128781A (ru) | 2020-03-24 |
| KR102148587B1 (ko) | 2020-08-26 |
| SG11201806383TA (en) | 2018-09-27 |
| US10323042B2 (en) | 2019-06-18 |
| ES2775674T3 (es) | 2020-07-27 |
| EP3419979B1 (en) | 2020-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261446A (en) | organic compounds | |
| EP3407888A4 (en) | ORGANIC CONNECTIONS | |
| EP3452423A4 (en) | SYNTHETIC POUZZOLANES | |
| DK3316969T3 (da) | Antibakterielle forbindelser | |
| EP3458073A4 (en) | SYNTHETIC COMPOSITION | |
| EP3380475A4 (en) | OCTAHYDROPYRROLO [3,4-C | |
| EP3529589B8 (en) | Cuvette | |
| DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| DK3537878T3 (da) | Algedræbende organismer | |
| EP3464336A4 (en) | COMPOUNDS | |
| EP3562484A4 (en) | ORGANIC COMPOUNDS | |
| EP3402829A4 (en) | COMPOUNDS COMPATIBLE WITH SILICONE | |
| DK3216503T4 (da) | Rutsjebanekøretøj | |
| ZA201804619B (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| DK3247749T3 (da) | Gule methinfarvestorfer | |
| ES2663220A8 (es) | Composicion panificable exenta de gluten | |
| EP3270920A4 (en) | Organic compounds | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| MA43791A (fr) | Composés de carbapénème | |
| DK3194408T3 (da) | Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor | |
| DK3672962T3 (da) | Morpholinylpyridonforbindelser | |
| BR112018005298A2 (pt) | compostos com terminação [(2-etoxi-5-trans-1-propen-1-il)-fenoxil] | |
| GB201607404D0 (en) | Organic compounds | |
| UA36871S (uk) | Печиво | |
| UA37342S (uk) | Печиво |